Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER reorganization

This article was originally published in The Tan Sheet

Executive Summary

Center for Drug Evaluation & Research Director Stephen Galson announces he will appoint a new associate center director "to focus on broad drug safety policy and safety communication" as part of the planned reorganization of the center in a staff memo Nov. 4. The memo provides an update to the proposed CDER reorganization that Galson announced Oct. 19 in conjunction with the appointment of a new Office of Drug Safety head. "Consolidating certain drug safety-related activities to report to this new associate center director" was also suggested by Galson in the update. In addition to drug safety goals, Galson hopes CDER will embrace the Critical Path Initiative and "improve regulatory and drug development science." His suggestions include creating a new office that will report to the center director and "provide a locus in the center to catalyze Critical Path activities." In the memo, Galson announces the appointment of Paul Seligman, MD, to associate center director...

You may also be interested in...



FDA Drug Safety Bulletin Being Considered To “Streamline” Communication

Implementation of an FDA standard drug safety bulletin will be one area of focus for the agency's new Associate Director for Safety Policy & Communication Paul Seligman

Cybersecurity: Guidance Docs To Come, But Legacy Devices Still A Challenge

Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.

Majority Of Spanish OTC Firms Investing Heavily In Digital

A recent ANEFP survey shows that the majority of Spanish OTC firms consider their digital strategies to be "very advanced."

Topics

UsernamePublicRestriction

Register

PS098793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel